Literature DB >> 25645833

In vitro activity of five quinolones and analysis of the quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan.

Yasuhiro Kawai1, Yukiko Nakura1, Tetsu Wakimoto2, Makoto Nomiyama3, Tsugumichi Tokuda3, Toshimitsu Takayanagi4, Jun Shiraishi5, Kenshi Wasada6, Hiroyuki Kitajima5, Tomio Fujita7, Masahiro Nakayama8, Nobuaki Mitsuda9, Isao Nakanishi10, Makoto Takeuchi8, Itaru Yanagihara11.   

Abstract

Ureaplasma spp. cause several disorders, such as nongonococcal urethritis, miscarriage, and preterm delivery with lung infections in neonates, characterized by pathological chorioamnionitis in the placenta. Although reports on antibiotic resistance in Ureaplasma are on the rise, reports on quinolone-resistant Ureaplasma infections in Japan are limited. The purpose of this study was to determine susceptibilities to five quinolones of Ureaplasma urealyticum and Ureaplasma parvum isolated from perinatal samples in Japan and to characterize the quinolone resistance-determining regions in the gyrA, gyrB, parC, and parE genes. Out of 28 clinical Ureaplasma strains, we isolated 9 with high MICs of quinolones and found a single parC gene mutation, resulting in the change S83L. Among 158 samples, the ParC S83L mutation was found in 37 samples (23.4%), including 1 sample harboring a ParC S83L-GyrB P462S double mutant. Novel mutations of ureaplasmal ParC (S83W and S84P) were independently found in one of the samples. Homology modeling of the ParC S83W mutant suggested steric hindrance of the quinolone-binding pocket (QBP), and de novo prediction of peptide structures revealed that the ParC S84P may break/kink the formation of the α4 helix in the QBP. Further investigations are required to unravel the extent and mechanism of antibiotic resistance of Ureaplasma spp. in Japan.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25645833      PMCID: PMC4356753          DOI: 10.1128/AAC.04262-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

1.  Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism.

Authors:  Michael L Beeton; Victoria J Chalker; Sailesh Kotecha; O Brad Spiller
Journal:  J Antimicrob Chemother       Date:  2009-06-30       Impact factor: 5.790

2.  Analysis of the quinolone-resistance determining region of the gyrA gene and the analogous region of the parC gene in Ureaplasma parvum and Ureaplasma urealyticum detected in first-void urine of men with non-gonococcal urethritis.

Authors:  Yasuyoshi Kamiya; Yasushi Shimada; Shin Ito; Mina Kikuchi; Mitsuru Yasuda; Yoshiaki Kawamura; Takashi Deguchi
Journal:  J Antimicrob Chemother       Date:  2012-10-22       Impact factor: 5.790

3.  Chromosomal mutations responsible for fluoroquinolone resistance in Ureaplasma species in the United States.

Authors:  Li Xiao; Donna M Crabb; Lynn B Duffy; Vanya Paralanov; John I Glass; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

4.  In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.

Authors:  C M Bebear; H Renaudin; A Charron; D Gruson; M Lefrancois; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Antibiotic susceptibilities and resistance genes of Ureaplasma parvum isolated in South Africa.

Authors:  S Govender; K Gqunta; M le Roux; B de Villiers; L J Chalkley
Journal:  J Antimicrob Chemother       Date:  2012-08-09       Impact factor: 5.790

6.  Fluoroquinolone resistance in Ureaplasma parvum in the United States.

Authors:  Lynn Duffy; John Glass; Geraldine Hall; Robin Avery; Raymond Rackley; Scott Peterson; Ken Waites
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

7.  Effects of Ureaplasma parvum lipoprotein multiple-banded antigen on pregnancy outcome in mice.

Authors:  Kaoru Uchida; Kumiko Nakahira; Kazuya Mimura; Takashi Shimizu; Francesco De Seta; Tetsu Wakimoto; Yasuhiro Kawai; Makoto Nomiyama; Koichi Kuwano; Secondo Guaschino; Itaru Yanagihara
Journal:  J Reprod Immunol       Date:  2013-10-19       Impact factor: 4.054

8.  Study of isolation of fluoroquinolone-resistant Ureaplasma urealyticum and identification of mutant sites.

Authors:  Wenbo Zhang; Yimou Wu; Weiguo Yin; Minjun Yu
Journal:  Chin Med J (Engl)       Date:  2002-10       Impact factor: 2.628

9.  Acquired genetic mechanisms of a multiresistant bacterium isolated from a treatment plant receiving wastewater from antibiotic production.

Authors:  Anna Johnning; Edward R B Moore; Liselott Svensson-Stadler; Yogesh S Shouche; D G Joakim Larsson; Erik Kristiansson
Journal:  Appl Environ Microbiol       Date:  2013-09-13       Impact factor: 4.792

10.  PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides.

Authors:  Pierre Thévenet; Yimin Shen; Julien Maupetit; Frédéric Guyon; Philippe Derreumaux; Pierre Tufféry
Journal:  Nucleic Acids Res       Date:  2012-05-11       Impact factor: 16.971

View more
  9 in total

1.  Antibacterial Resistance in Ureaplasma Species and Mycoplasma hominis Isolates from Urine Cultures in College-Aged Females.

Authors:  Marissa A Valentine-King; Mary B Brown
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Tetracycline Resistance Mediated by tet(M) Has Variable Integrative Conjugative Element Composition in Mycoplasma hominis Strains Isolated in the United Kingdom from 2005 to 2015.

Authors:  Victoria J Chalker; Martin G Sharratt; Christopher L Rees; Oliver H Bell; Edward Portal; Kirsty Sands; Matthew S Payne; Lucy C Jones; Owen B Spiller
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  Antibiotic Susceptibility and Sequence Type Distribution of Ureaplasma Species Isolated from Genital Samples in Switzerland.

Authors:  Sarah C Schneider; Regula Tinguely; Sara Droz; Markus Hilty; Valentina Donà; Thomas Bodmer; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

4.  Antimicrobial Resistance in Clinical Ureaplasma spp. and Mycoplasma hominis and Structural Mechanisms Underlying Quinolone Resistance.

Authors:  Ting Yang; Lianlian Pan; Ningning Wu; Lin Wang; Zhen Liu; Yingying Kong; Zhi Ruan; Xinyou Xie; Jun Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

5.  In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species.

Authors:  Yingying Kong; Chao Li; Gangfeng Li; Ting Yang; Mohamed S Draz; Xinyou Xie; Jun Zhang; Zhi Ruan
Journal:  Microbiol Spectr       Date:  2022-05-09

6.  Spread of multidrug resistance among Ureaplasma serovars, Tunisia.

Authors:  Safa Boujemaa; Béhija Mlik; Amina Ben Allaya; Helmi Mardassi; Boutheina Ben Abdelmoumen Mardassi
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-23       Impact factor: 4.887

7.  MYCO WELL D-ONE detection of Ureaplasma spp. and Mycoplasma hominis in sexual health patients in Wales.

Authors:  Daniel J Morris; Lucy C Jones; Rebecca L Davies; Kirsty Sands; Edward Portal; Owen B Spiller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-07-28       Impact factor: 3.267

8.  Validation of the loop-mediated isothermal amplification method for rapid and sensitive detection of Ureaplasma species in respiratory tracts of preterm infants.

Authors:  Yuta Mikami; Kazumasa Fuwa; Eriko Arima; Yasuo Suda; Itaru Yanagihara; Satoshi Ibara
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

9.  Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial.

Authors:  Ian Boostrom; Yohan Bala; Jelena Minic Vasic; Jelena Gluvakov; Emmanuel Chanard; Andrew H Barratt; Kirsty Sands; Edward Portal; Laurence Devigne; Lucy C Jones; Owen B Spiller
Journal:  J Antimicrob Chemother       Date:  2021-11-12       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.